Moteur de recherche d’entreprises européennes
Financement de l’UE (6 478 738 €) : Développement de DIALIVE, un nouveau dispositif de dialyse hépatique pour le traitement des patients atteints d’insuffisance hépatique aiguë ou chronique (ACLF) Hor15/12/2016 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Développement de DIALIVE, un nouveau dispositif de dialyse hépatique pour le traitement des patients atteints d’insuffisance hépatique aiguë ou chronique (ACLF)
Liver disease incidence is increasing and about 170K patients die from liver failure each year in Europe. In liver failure, the accumulation of protein bound toxins and increased susceptibility to infection cause multiorgan failure and death. Liver transplantation is the only treatment known to prolong the life but is limited by availability of organs. A clinically efficacious ‘liver dialysis device’ is an unmet clinical need. The ALIVER Consortium has developed and optimised a novel ‘liver dialysis device’, DIALIVE. The DIALIVE device is protected by world-wide patents and is based upon our discovery that (i) albumin, a circulating protein involved in detoxification is reduced irreversibly in function and (ii) endotoxemia contributes to increased risk of infection in liver failure. DIALIVE incorporates albumin removal and replacement and, endotoxin removal and is a TRL5. In animal models of liver failure, DIALIVE was shown to be easy to use, safe, reduced endotoxemia and, improved albumin and immune function and, prolonged survival. The ALIVER Consortium, which is comprised of experts in liver failure, SMEs and charities proposes to perform clinical trials of DIALIVE in patients with acute on chronic liver failure (ACLF). During the grant period a CE-mark will be obtained and the device will progress to a TRL7/8. Consultation with Regulatory bodies confirms that if the trials are successful, a CE-mark is highly likely. Grifols, a large plasma proteins company is a potential licensee of the technology if the studies proposed by the ALIVER Consortium are positive. We plan to take the project through regulatory and ethics approval and perform a study to define its safety in ACLF patients in 18 European hospitals; define health economic benefits to the EU and define a reimbursement strategy. The results will be disseminated widely and results exploited to benefit patients, EU healthcare system, create new jobs and grow healthcare Industry in Europe.
| ALBUTEC GmbH | 199 360 € |
| Assistance Publique Hopitaux de Paris | 46 515 € |
| EUROPEAN Association FOR THE STUDYOF THE LIVER | 0,00 € |
| 120 500 € | |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | 0,00 € |
| Fakkel BVBA | 1 158 750 € |
| 261 250 € | |
| Royal Free London NHS Foundation Trust | 433 750 € |
| 227 964 € | |
| 119 577 € | |
| 1 089 621 € | |
| Yaqrit Ltd. | 2 821 450 € |
https://cordis.europa.eu/project/id/733057
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "ALBUTEC GmbH - Financement de l’UE (6 478 738 €) : Développement de DIALIVE, un nouveau dispositif de dialyse hépatique pour le traitement des patients atteints d’insuffisance hépatique aiguë ou chronique (ACLF)"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
